£1.1M
Norcliffe Capital led the latest investment as the cancer diagnostics firm reached its £3.5m target.
CD
ClinSpec Diagnostics
ClinSpec Diagnostics develops rapid liquid biopsies for early cancer detection.
£3.5MTotal raised
ClinSpec Diagnostics develops liquid biopsies for early cancer detection using infrared light and artificial intelligence. The Glasgow based firm operates as a spinout from the University of Strathclyde.
Categories
Team
MH
Mark Hegarty
CEO
SH
Steve Howell
Chairman
Matthew Baker
Dr
Matthew brings diagnostics, medtech, and AI leadership experience as founder, president, and chief executive officer at Dxcover. He is also a professor of early diagnostics at the University of Lancashire.
Investors
- £1.1M
- £2.4M
Funding history
£2.4M
The funding round was led by Mercia and will support the firm in progressing its multi-cancer diagnostic programmes.